Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07280702 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Study acronym: COMBo
StatusRecruiting
PhasePhase 4
Started2026-06-16
View on ClinicalTrials.gov ↗

Amendment history

2026-08-27
Study Identification, Study Status, Contacts/Locations v3
Recruitment opened
Start dateestimated 2026-04-15→confirmed 2026-06-16
Study sitesdetails revised at 1 of 1 site
2026-04-06
Study Identification, Study Status v2
Study title+1 characters
Deucravacitinib-TNFTNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
2026-02-17
Study Status v1
Start date2025-12-15→2026-04-15
2025-12-03
Original filing
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Trial Details
NCT Number NCT07280702
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Psoriatic Arthritis (PsA)
Enrollment 128 participants
Start Date 2026-06-16
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-01